Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 4/20 | 0.73 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.71 |
| ▸ | LDLR | P01130 | 2/20 | 0.70 |
| ▸ | KIT | P10721 | 2/20 | 0.70 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.70 |
| ▸ | ABL1 | P00519 | 8/20 | 0.67 |
| ▸ | BCR | P11274 | 7/20 | 0.67 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | RAF1 | P04049 | 1/20 | 0.63 |
| ▸ | HCK | P08631 | 1/20 | 0.62 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.62 |
| ▸ | BTK | Q06187 | 1/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589522 | 1.00 | NR2E1 (0.73) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL13659898 | 0.91 | NR2E1 (0.77) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL15442255 | 0.90 | NR2E1 (0.71) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL27143130 | 0.89 | NR2E1 (0.71) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL24532047 | 0.88 | NR2E1 (0.73) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL4254144 | 0.88 | NR2E1 (0.73) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL21612152 | 0.88 | CSF1R (0.71) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL3433139 | 0.88 | NR2E1 (0.60) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL22529506 | 0.88 | EPHB2 (0.55) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL22065195 | 0.87 | EPHB2 (0.75) | NR2E1EPHB2LDLRKITPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| CN-115697485-B | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-4157447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-04-05 | — | — | EP | disclosed |
| CN-115697485-A | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-110194772-B | Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-20220081440-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081440-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | NR2E1 2434/4885EPHB2 3120/4885LDLR 4080/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | NR2E1 2434/4885EPHB2 3120/4885LDLR 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.